• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Sequana Medical announces results of Special General Meeting of Shareholders

    6/26/23 12:00:00 PM ET
    $AORT
    $PHAR
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AORT alert in real time by email

    PRESS RELEASE

    REGULATED INFORMATION

    26 June 2023, 06:00 pm CEST



    Dr. Kenneth Macleod appointed as non-executive director

    Ghent, Belgium – 26 June 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces that all proposed resolutions submitted to the Special General Meeting of Shareholders were approved at the meeting held today at 09:00 am CEST.

    The items on the agenda of the meeting included the appointment of Dr. Kenneth Macleod as non-executive director of the Company and the approval in accordance with Article 7:151 of the Belgian Companies and Associations Code of the terms and conditions of the subscription rights issued in the framework of the equity offering that was successfully completed on 25 April 2023 in the event of certain change of control events. The minutes of the shareholders' meeting can be accessed on the Company's website.

    Dr. Kenneth Macleod is a Partner at Rosetta Capital, a venture capital firm focused on life sciences and medical devices. Dr Macleod has over 35 years' experience in the life sciences sector in a career combining senior operating roles in healthcare companies (Abbott Laboratories, Serono SA) and life science fund management (SV Health Investors, Paul Capital Partners, Visium Healthcare Partners). Dr Macleod currently holds board positions at JenaValve Technology Inc. and Oxular Limited and has previously held board roles including at Pharming Group N.V. (NASDAQ:PHAR) and On-X Life Technologies, Inc., a mechanical heart valve company sold to Cryogenics Inc. (NASDAQ:AORT). Dr Macleod received a BSc in Biological Sciences from the University of Manchester and a D.Phil. from the University of York.

    Pierre Chauvineau, Chairman of Sequana Medical's Board of Directors, commented: "Ken brings tremendous expertise and experience to the Board of Directors of Sequana Medical at this key time as we build on our recent successful trial results in liver disease and heart failure. We are gearing up for the commercialization of our alfapump in the US following the submission of our Pre-Market Approval to the FDA planned before the end of the year and enrolling the first patient in MOJAVE, our US DSR study in heart failure."

    Commenting on his appointment, Dr. Macleod added: "Sequana Medical has made great progress with both its alfapump and DSR programs for the treatment of fluid overload due to liver cirrhosis and heart failure, two widespread disease indications where patients are in urgent need for new and better treatments. I am looking forward to contributing to the work of the Board of Directors to help deliver the next stage of the Company's development."

    For more information, please contact:

    Sequana Medical

    Lies Vanneste

    Director Investor Relations

    E: [email protected]

    T: +32 (0)498 05 35 79

    Optimum Strategic Communications

    Nick Bastin, Jonathan Edwards, Vici Rabbetts

    E: [email protected]

    T: +44 (0) 208 078 4357

    About Sequana Medical

    Sequana Medical NV is a pioneer in treating fluid overload, a serious and frequent clinical complication in patients with liver disease, heart failure and cancer. These patients can have up to 15 liters of extra fluid in their bodies, causing major medical issues including increased mortality, repeated hospitalizations, severe pain, difficulty breathing and restricted mobility that severely impacts daily life. Although diuretics are standard of care, the problem is that in many patients they are no longer effective and / or tolerable. There are limited effective treatment options for these patients, resulting in poor clinical outcomes, high costs and a major impact on their quality of life. Sequana Medical is seeking to provide innovative treatment options for this large and growing "diuretic-resistant" patient population.

    alfapump® and DSR® are Sequana Medical's proprietary platforms that work with the body to treat diuretic-resistant fluid overload, delivering major clinical and quality of life benefits for patients and reducing costs for healthcare systems. The Company has reported positive primary endpoint data from the North American pivotal POSEIDON trial of the alfapump in recurrent or refractory ascites due to liver cirrhosis, enabling the filing of a Pre-Market Approval (PMA) application with the FDA, planned for H2 2023. Having delivered clinical proof-of-concept for DSR as a disease-modifying drug program for the treatment of heart failure, the Company is preparing to commence MOJAVE, a US randomized controlled multi-center Phase 1/2a clinical trial of DSR 2.0, with initial data expected in Q4 2023.

    Sequana Medical is listed on Euronext Brussels (Ticker: SEQUA.BR) and headquartered in Ghent, Belgium. For further information, please visit www.sequanamedical.com.

    Important Regulatory Disclaimers

    The alfapump® system is currently not approved in the United States or Canada. In the United States and Canada, the alfapump system is currently under clinical investigation (POSEIDON Trial) and is being studied in adult patients with refractory or recurrent ascites due to liver cirrhosis. DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. There is no link between DSR therapy and ongoing investigations with the alfapump system in Europe, the United States or Canada.

    Note: alfapump® and DSR® are registered trademarks.

    Forward-looking statements

    This press release may contain predictions, estimates or other information that might be considered forward-looking statements.

    Such forward-looking statements are not guarantees of future performance. These forward-looking statements represent the current judgment of Sequana Medical on what the future holds, and are subject to risks and uncertainties that could cause actual results to differ materially. Sequana Medical expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release, except if specifically required to do so by law or regulation. You should not place undue reliance on forward-looking statements, which reflect the opinions of Sequana Medical only as of the date of this press release.

    Attachments

    • Press release_Results SGM 2023_26 June 2023_NL_vF
    • Press release_Results SGM 2023_26 June 2023_ENG_vF


    Primary Logo

    Get the next $AORT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AORT
    $PHAR

    CompanyDatePrice TargetRatingAnalyst
    Pharming Group N.V. ADS each representing 10
    $PHAR
    12/9/2024$14.00Buy
    Jefferies
    Artivion Inc.
    $AORT
    10/23/2024$33.00Mkt Outperform
    JMP Securities
    Artivion Inc.
    $AORT
    9/27/2022$32.00 → $28.00Buy
    Lake Street
    Artivion Inc.
    $AORT
    8/8/2022$32.00Buy
    Lake Street
    Artivion Inc.
    $AORT
    3/3/2022$30.00Buy
    Stifel
    Artivion Inc.
    $AORT
    2/18/2022$39.00 → $30.00Buy
    Needham
    More analyst ratings

    $AORT
    $PHAR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Pharming Group N.V. ADS each representing 10

      SC 13G/A - Pharming Group N.V. (0001828316) (Subject)

      11/14/24 6:17:36 AM ET
      $PHAR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Pharming Group N.V. ADS each representing 10

      SC 13G - Pharming Group N.V. (0001828316) (Subject)

      11/8/24 3:03:47 PM ET
      $PHAR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Artivion Inc.

      SC 13G/A - ARTIVION, INC. (0000784199) (Subject)

      11/8/24 10:29:29 AM ET
      $AORT
      Medical/Dental Instruments
      Health Care

    $AORT
    $PHAR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Jefferies initiated coverage on Pharming Group N.V. with a new price target

      Jefferies initiated coverage of Pharming Group N.V. with a rating of Buy and set a new price target of $14.00

      12/9/24 8:05:53 AM ET
      $PHAR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JMP Securities initiated coverage on Artivion with a new price target

      JMP Securities initiated coverage of Artivion with a rating of Mkt Outperform and set a new price target of $33.00

      10/23/24 6:17:27 AM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Lake Street reiterated coverage on Artivion with a new price target

      Lake Street reiterated coverage of Artivion with a rating of Buy and set a new price target of $28.00 from $32.00 previously

      9/27/22 11:06:42 AM ET
      $AORT
      Medical/Dental Instruments
      Health Care

    $AORT
    $PHAR
    Leadership Updates

    Live Leadership Updates

    See more
    • Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders

      Leiden, the Netherlands, March 4, 2025: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) announces today that the Extraordinary General Meeting of Shareholders (EGM) has adopted all proposals on the EGM agenda. Shareholders approved the appointment of Mr. Fabrice Chouraqui as Executive Director and Chief Executive Officer for a term of four years. As a result, Mr. Chouraqui succeeds Mr. Sijmen de Vries with immediate effect. To ensure a smooth hand-over of tasks and responsibilities, Mr. de Vries will remain a strategic advisor to the new CEO until December 31, 2025. In addition, shareholders also approved the proposal to approve certain components of the remuneration pac

      3/4/25 9:15:00 AM ET
      $PHAR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer

      Leiden, the Netherlands, January 21, 2025: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) announces today that the Board of Directors has nominated Fabrice Chouraqui to become Pharming's new Executive Director and Chief Executive Officer, succeeding Sijmen de Vries. Pharming will nominate Mr. Chouraqui for the appointment as Executive Director and Chief Executive Officer for a term of four years at an upcoming Extraordinary General Meeting of Shareholders (EGM). Information regarding the EGM, including the notice to convene, will be shared shortly in a separate press release. Upon the appointment of Mr. Chouraqui, Sijmen de Vries will resign from the Board of Directors.

      1/21/25 1:00:00 AM ET
      $PHAR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Artivion Appoints Lance A. Berry as Executive Vice President, Chief Financial Officer; Announces Retirement of D. Ashley Lee, Chief Financial Officer

      Reaffirms Financial Guidance Provided on November 2, 2023 ATLANTA, Dec. 6, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease today announced the appointment of Lance A. Berry as the Company's Chief Financial Officer, effective as of December 4, 2023. In this role, Mr. Berry joins Artivion's executive leadership team and replaces Mr. D. Ashley Lee, who will retire at the end of the year after a successful and long tenure with the Company and a distinguished career in the medical device industry. Artivion also reaffirmed its full-year 2023 financial guidance that was provided on November 2, 2023.

      12/6/23 4:15:00 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care

    $AORT
    $PHAR
    SEC Filings

    See more
    • SEC Form 6-K filed by Pharming Group N.V. ADS each representing 10

      6-K - Pharming Group N.V. (0001828316) (Filer)

      5/8/25 6:59:48 AM ET
      $PHAR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Artivion Inc.

      10-Q - ARTIVION, INC. (0000784199) (Filer)

      5/6/25 3:10:43 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Artivion Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ARTIVION, INC. (0000784199) (Filer)

      5/5/25 4:08:44 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care

    $AORT
    $PHAR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Semedo Anthony B. bought $53,140 worth of shares (2,100 units at $25.30), increasing direct ownership by 4% to 35,659 units (SEC Form 4)

      4 - ARTIVION, INC. (0000784199) (Issuer)

      3/5/25 4:01:01 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care

    $AORT
    $PHAR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Pharming Group reports first quarter 2025 financial results and provides business update

      First quarter 2025 total revenues increased by 42% to US$79.1 million, compared to the first quarter 2024 RUCONEST® revenue increased by 49% to US$68.6 million, compared to the first quarter 2024, reflecting continued momentum and the product's unique position in the on-demand HAE marketJoenja® (leniolisib) volume increase by 18% and revenue increased by 9% to US$10.5 million, compared to the first quarter of 2024, with accelerating patient uptake compared to the prior few quartersOperating profit, adjusted to exclude the impact of non-recurring Abliva acquisition-related expenses, amounted to US$0.8 million compared to a US$16.3 million loss in the first quarter 2024Launched Joenja® (leniol

      5/8/25 1:00:00 AM ET
      $PHAR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Artivion Reports First Quarter 2025 Financial Results

      First Quarter Highlights: Achieved revenue of $99.0 million in the first quarter of 2025 versus $97.4 million in the first quarter of 2024, an increase of 2% on a GAAP basis and 4% on a non-GAAP constant currency basisNet loss was $(0.5) million, or $(0.01) per fully diluted share and non-GAAP net income was $2.5 million, or $0.06 per fully diluted share in the first quarter of 2025Adjusted EBITDA increased 1% to $17.5 million in the first quarter of 2025 compared to $17.3 million in the first quarter of 202430-day data from Endospan's NEXUS TRIOMPHE IDE trial presented at the AATS Annual Meeting demonstrated a 63% reduction in the major adverse event (MAE) rate compared with reference perf

      5/5/25 4:05:00 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Artivion Announces Presentation of New Clinical Data from NEXUS TRIOMPHE IDE Trial at the 105th American Association for Thoracic Surgery (AATS) Annual Meeting

      30-Day Data from Endospan's NEXUS TRIOMPHE IDE Trial Demonstrate 63% Reduction in Major Adverse Event (MAE) Rate compared with Reference Performance Goal ATLANTA, May 5, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the presentation of new clinical data from Endospan's NEXUS TRIOMPHE trial at the 105th American Association for Thoracic Surgery (AATS) Annual Meeting in Seattle, Washington. The data presented analyzed clinical outcomes across a 54-patient chronic aortic dissection statistical cohort at 30 days following treatment with NEXUS.  Patients enrolled were at high risk for open surgical repair

      5/5/25 7:00:00 AM ET
      $AORT
      Medical/Dental Instruments
      Health Care

    $AORT
    $PHAR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, General Counsel Holloway Jean F exercised 19,092 shares at a strike of $21.55 and sold $425,510 worth of shares (18,020 units at $23.61), increasing direct ownership by 0.55% to 197,184 units (SEC Form 4)

      4 - ARTIVION, INC. (0000784199) (Issuer)

      3/12/25 3:41:12 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Chief Commercial Officer Davis John E exercised 15,910 shares at a strike of $21.55 and sold $356,549 worth of shares (15,100 units at $23.61), increasing direct ownership by 0.39% to 208,778 units (SEC Form 4)

      4 - ARTIVION, INC. (0000784199) (Issuer)

      3/12/25 3:32:23 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • President & CEO Mackin James P exercised 75,615 shares at a strike of $21.55, was granted 115,701 shares and sold $2,190,848 worth of shares (88,439 units at $24.77), increasing direct ownership by 13% to 865,283 units (SEC Form 4)

      4 - ARTIVION, INC. (0000784199) (Issuer)

      3/10/25 5:18:53 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care

    $AORT
    $PHAR
    Financials

    Live finance-specific insights

    See more
    • Pharming Group reports first quarter 2025 financial results and provides business update

      First quarter 2025 total revenues increased by 42% to US$79.1 million, compared to the first quarter 2024 RUCONEST® revenue increased by 49% to US$68.6 million, compared to the first quarter 2024, reflecting continued momentum and the product's unique position in the on-demand HAE marketJoenja® (leniolisib) volume increase by 18% and revenue increased by 9% to US$10.5 million, compared to the first quarter of 2024, with accelerating patient uptake compared to the prior few quartersOperating profit, adjusted to exclude the impact of non-recurring Abliva acquisition-related expenses, amounted to US$0.8 million compared to a US$16.3 million loss in the first quarter 2024Launched Joenja® (leniol

      5/8/25 1:00:00 AM ET
      $PHAR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Artivion Reports First Quarter 2025 Financial Results

      First Quarter Highlights: Achieved revenue of $99.0 million in the first quarter of 2025 versus $97.4 million in the first quarter of 2024, an increase of 2% on a GAAP basis and 4% on a non-GAAP constant currency basisNet loss was $(0.5) million, or $(0.01) per fully diluted share and non-GAAP net income was $2.5 million, or $0.06 per fully diluted share in the first quarter of 2025Adjusted EBITDA increased 1% to $17.5 million in the first quarter of 2025 compared to $17.3 million in the first quarter of 202430-day data from Endospan's NEXUS TRIOMPHE IDE trial presented at the AATS Annual Meeting demonstrated a 63% reduction in the major adverse event (MAE) rate compared with reference perf

      5/5/25 4:05:00 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Pharming Group reports fourth quarter and full year 2024 financial results and provides business update

      Full year 2024 total revenues increased by 21% to US$297.2 million and exceeded our guidance, driven by record RUCONEST® revenue and strong Joenja® (leniolisib) growth Fourth quarter 2024 total revenues increased by 14% to US$92.7 million, compared to the fourth quarter 2023RUCONEST® full year revenue increased by 11% to US$252.2 million and fourth quarter revenue increased by 9% to US$79.6 million, compared to the fourth quarter 2023Joenja® revenue increased by 147% to US$45.0 million in the first full year post-launch and fourth quarter revenue increased by 66% to US$13.1 million, compared to the fourth quarter 2023Fourth quarter operating profit increased to US$6.7 million from US$1.1 mil

      3/13/25 2:00:00 AM ET
      $PHAR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AORT
    $PHAR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • May 23, 2023 - FDA Roundup: May 23, 2023

      For Immediate Release: May 23, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Monday, the FDA and the Veterans Health Administration announced a new collaboration to jointly develop emergency preparedness and response tools and protocols intended to help increase medical product manufacturing capacity and flexibility, and improve resilie

      5/23/23 4:06:19 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care